Total Reports
11
FDA CVM filings
Dog /
2026 FDA CVM data 11 reports on file official source
New Guinea Singing Dog — FDA Adverse Event Profile
Adverse-event records and label data for New Guinea Singing Dog (Dog), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
New Guinea Singing Dog (Dog) has 11 FDA adverse event reports on record, with 0 deaths reported (0.0% death rate) — ranking #430 by report volume. The most frequently reported reaction is Lethargy (see also Central nervous system depression in 'Neurological') (2 cases). The top associated drug is Moxidectin. Average age at report: 5.0 years.
Deaths Reported
0
of 11 reports
Death Rate
0.0%
death-coded share
Avg Age at Report
5.0 yr
no age data
Death-Coded Outcome Share
New Guinea Singing Dog death-coded reports 0.0%
Database median
0.0% of 11 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Top Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 2
Lack of efficacy (endoparasite) - heartworm 2
INEFFECTIVE, ATOPY CONTROL 1
Inappropriate schedule of drug administration 1
Skin lesion NOS 1
Injection site crust 1
Injection site serosanguinous discharge 1
Skin abscess 1
Lack of efficacy (endoparasite) - NOS 1
INEFFECTIVE, SEDATION 1
Underdose 1
Drug administration error 1
Emesis 1
Anorexia 1
Tachycardia 1
Most Referenced Drugs
Moxidectin 5
Oclacitinib Maleate 2
Butorphanol 2
Anti-Il31 Mab Mcs Lot #1283563 1
Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str 1
Dexmedetomidine Hydrochloride 1
Pyrantel Pamoate;Sarolaner 1
Propofol 1
Isoflurane 1
Melarsomine Dihydrochloride 1
Carprofen 1
Outcome Breakdown
Recovered/Normal
5 (45.5%)
Ongoing
4 (36.4%)
Outcome Unknown
2 (18.2%)
Gender Distribution
Unknown 11 (100.0%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2018 | 1 | |
| 2019 | 3 | |
| 2020 | 3 | |
| 2021 | 4 | |
New Guinea Singing Dog Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, New Guinea Singing Dog accounts for 11 submitted reports and currently ranks #430 by report volume within the dog population. Of those reports, 0 involved a death outcome — a 0.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 5.0 years. These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for New Guinea Singing Dog are Lethargy (see also Central nervous system depression in 'Neurological') (2 reports), Lack of efficacy (endoparasite) - heartworm (2 reports), INEFFECTIVE, ATOPY CONTROL (1 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Moxidectin appears in 5 reports and is the single most-referenced drug, followed by Oclacitinib Maleate (2) and Butorphanol (2). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same dog species.
Outcome coding on the 11 reports with a recorded status is dominated by Recovered/Normal (45.5% of coded outcomes). Annual submission volume ranges from 2,018 to 2,021 reports across the 4 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual dog.
Understanding New Guinea Singing Dog Adverse Event Data
New Guinea Singing Dog has 11 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
A 0.0% death rate is below average in the FDA adverse event database, suggesting reported events tend toward less severe outcomes.
The most frequently referenced drug in adverse reports is Moxidectin, appearing in 5 reports. This may indicate widespread use of the medication rather than a specific safety concern for New Guinea Singing Dog.
Other Dog Breeds
Retriever - Labrador
90,806 reports · 360.0% death rate
Crossbred Canine/dog
68,210 reports · 320.0% death rate
Dog (unknown)
47,381 reports · 870.0% death rate
Retriever - Golden
34,475 reports · 370.0% death rate
Shepherd Dog - German
31,142 reports · 430.0% death rate
Chihuahua
30,657 reports · 420.0% death rate
Frequently Asked Questions
How many FDA adverse event reports involve New Guinea Singing Dog? ▼
There are 11 adverse event reports involving New Guinea Singing Dog in the FDA database, with 0 reports involving death (0.0% death rate). New Guinea Singing Dog ranks #430 by report volume.
What are the most common adverse reactions reported for New Guinea Singing Dog? ▼
The most commonly reported adverse reactions for New Guinea Singing Dog are Lethargy (see also Central nervous system depression in 'Neurological') (2 reports), Lack of efficacy (endoparasite) - heartworm (2 reports), INEFFECTIVE, ATOPY CONTROL (1 reports), Inappropriate schedule of drug administration (1 reports), Skin lesion NOS (1 reports).
What drugs are most frequently associated with New Guinea Singing Dog adverse events? ▼
The drugs most frequently referenced in New Guinea Singing Dog adverse event reports are Moxidectin (5 reports), Oclacitinib Maleate (2 reports), Butorphanol (2 reports), Anti-Il31 Mab Mcs Lot #1283563 (1 reports), Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str (1 reports).
What is the average age of New Guinea Singing Dog in adverse event reports? ▼
The average age of New Guinea Singing Dog at the time of adverse event reports is 5.0 years.
Does a high number of adverse event reports mean New Guinea Singing Dog is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this New Guinea Singing Dog safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
New Guinea Singing Dog ranks #430 by total report volume. Death rate (0.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial